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Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in
cyclosporin A nephrotoxlcity. Cyclosporin A (CsA) administration to
rats is associated with a selective increase in urinary excretion of
immunoreactive thromboxane B2 (i-TxB2), the stable breakdown prod-
uct of TxA2. The exaggerated synthesis of TxA2 may play a role in the
reduction of glomerular filtration rate (GFR) observed both in animals
and humans undergoing CsA treatment. The present study was de-
signed to get further insight into the origin of the abnormal i-TxB2
urinary excretion. Rats given orally CsA (50 mg/kg/day) for 30 days had
a significant increase in the urinary excretion of both 2,3-dinor-TxB2
and TxB2 measured by technique of capillary column gas chromatog-
raphy-negative ion chemical ionization mass spectrometry (HRGC-
NICIMS). Urinary TxB2 is more likely to reflect the renal synthesis of
the parent compound, whereas 2,3-dinor-TxB2 is considered to reflect
the amount of TxB2 formed in the circulation. Experiments in isolated
perfused kidney (IPK) taken from animals given CsA for 30 days
showed a lower percentage increase in urinary TxB2 over vehicle
treated animals. Moreover in IPK the ratio 2,3-dinor-TxB2/TxB2 was
lower than in vivo. The amount of i-TxB2 detectable in serum of animals
given CsA was not different from that of control animals. In contrast,
isolated glomeruli taken from rats given CsA had an increase in their
TxA2 synthesis measured as i-TxB2 in the supernatants. Ultrastructural
studies on kidney specimens from animals given CsA showed a focal
glomerular endothelial damage together with a marked infiltration of
blood borne cells of monocyte-macrophage type in the glomerular tuft.
In contrast, kidney specimens taken from IPK preparations were
devoid of inflammatory cells. In vitro CsA did not interfere with platelet
arachidonic acid (AA) metabolism as shown by a normal i-TxB2
generation in vitro by rat platelet-rich plasma (PRP) exposed to CsA
and then challenged with AA or ADP. Similarly isolated glomeruli and
isolated proximal tubules from normal rats when challenged with CsA
in vitro converted AA into TxA2 normally. It is suggested that the cause
of the increased urinary excretion or 2,3-dinor-TxB2 is the consequence
of intrarenal platelet and macrophage activation, probably triggered by
the endothelial damage. The parallel increase in the urinary excretion of
unmetabolized TxB2 is likely to reflect a concomitant activation of
resident renal cell AA metabolism induced by CsA.
Cyclosporin A (CsA) is a fungal cyclic polypeptide that has
been shown to suppress both humoral and cell-mediated immu-
nity by affecting the early steps of T-cell activation [1, 2].
Because of its peculiar and selective activity on immune system
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it is now considered as one of the most promising drugs for the
management of graft rejection 13]. However, CsA has several
side effects, the most disturbing of which in clinical practice is
nephrotoxicity [4—7]. The possible cause of CsA nephrotoxicity
has been extensively investigated in the last few years in both
experimental animals and humans. Thus, stimulation of the
renin-angiotensin system [81 or renal sympathetic nervous
system [9, 10] has been recently proposed to play a role in the
deterioration of renal function observed after chronic adminis-
tration of CsA. Our group has demonstrated recently that
chronic CsA administration to rats is associated with a selective
increase in urinary excretion of immunoreactive thromboxane
B2 (i-TxB2), the stable breakdown product of TxA2, and sug-
gested an exaggerated renal synthesis of TxA2 as the cause of
CsA-induced decrease in glomerular filtration rate (GFR) [11].
The observation that a selective TxA2 synthase inhibitor at a
dose that inhibits urinary excretion of i-TxB2 can partially
reverse CsA-induced decrease in GFR supports the possibility
of a functional role for TxA2 in mediating the altered renal
hemodynamics, which is likely to be the primum movens of
CsA nephrotoxicity [111.
The origin of the abnormal i-TxB2 urinary excretion in
CsA-treated animals has not been established. Since kidney
cells have been found to generate prostaglandins and throm-
boxane [12], one can hypothesize that resident glomerular cells
(that is, epithelial and/or mesangial cells) are responsible for the
increased urinary excretion of i-TxB2 in CsA treated animals.
Alternatively, the increase in urinary excretion of i-TxB2 could
be due to locally activated, blood borne cells (especially plate-
lets), which may either infiltrate the glomerular tuft or be
activated during their passage through the kidney. The possi-
bility that the increased urinary excretion of i-TxB2 is due to
extrarenal platelet activation has also to be taken into account.
Some recent advances in our understanding of thromboxane
metabolism may be pertinent to the issue. Moreover, a sensitive
and selective stable isotope dilution technique for the measure-
ment of urinary TxB2 and 2,3-dinor-TxB2 by high resolution gas
chromatography-negative ion chemical ionization mass spec-
trometry (HRGC-NICIMS) has become available [13]. By this
technique, we could easily distinguish 2,3-dinor-TxB2, the
major urinary metabolite of systemically administered TxB2
[14], from TxB2. Under physiologic circumstances the dinor
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metabolite is likely to derive in large part from extrarenal
platelet activation, while urinary TxB2 is considered to be of
renal origin [15].
We have designed the present experiments with the aim: 1.)
to confirm the renal versus extrarenal origin of urinary TxB2 in
CsA treated animals; 2.) to establish whether the cell(s) respon-
sible for the increased TxA2 formation in CsA treated animals
are blood borne cells activated during their passage through
renal circulation or resident renal cells. The results of our study
may have obvious implications for future therapeutical strate-
gies aimed at reducing CsA nephrotoxicity by pharmacologic
manipulation of arachidonic acid (AA) metabolism.
Methods
Experimental protocol
Male Sprague-Dawley rats (Charles River Breeding Labora-
tories, Calco, Italy), weighing 250 to 275 g at the start of the
experiment, were housed in a constant temperature room with
a 12-hour light-dark cycle and were maintained on standard rat
chow (Altromin-Rieper, Vandoies, Italy). Two groups of ani-
mals were considered. Group 1 (N = 10) received by gavage a
daily oral dose (50 mg/kg) of cyclosporin A (Sandoz, Basle,
Switzerland) for 30 days. This treatment has been previously
shown to induce renal insufficiency and to increase urinary
excretion rate of i-TxB2, the stable breakdown product of TxA2,
in normal rats [11]. Group 2 (N = 10) received a daily oral dose
(1 ml) of the vehicle, polyoxyethyleneted castor oil (Sabo,
Bergamo, Italy) in which CsA was dissolved, for 30 days and
was considered to be the control group. Since it has been
suggested that CsA-induced weight loss may be due to extra-
cellular fluid volume depletion, control rats were pair-fed and
watered. Twenty-four hour urine samples were collected using
metabolic cages, immediately frozen and stored at —20°C. The
urinary excretion of i-TxB2, which primarily reflects the renal
synthesis of the unstable parent compound TxA2, was mea-
sured by radioimmunoassay (RIA) after extraction and silicic
acid column chromatography. The antiserum for RIA showed a
10.5% cross-reactivity with 2,3-dinor-TxB2, which is the major
metabolite of systemically administered TxB2 in humans [14].
Since no data were available on 2,3-dinor-TxB2 excretion in rats
under normal or pathological conditions, we determined the
amount of TxB2 and 2,3-dinor-TxB2 in urine from rats treated
with CsA or vehicle by HRGC-NICIMS. Blood samples for
determination of serum i-TxB2 generation were collected from
the tail vein. All these parameters were studied before (basal)
and after 30 days of CsA or vehicle administration. At the end
of the study, glomerular filtration rate (GFR) and renal plasma
flow (RPF) were assessed by inulin and p-aminohippuric acid
(PAH) clearance methods. Basal values for GFR and RPF were
obtained in an additional age- and weight-matched group of five
control animals. After the clearances, kidneys were removed
and histological studies on kidney specimens were performed
by light and electron microscopy. From the remaining tissue,
glomeruli were isolated and their ability to produce i-TxB2 was
assessed. Studies were performed in isolated perfused, rat
kidney preparations to discriminate between resident renal cells
and intraglomerular inflammatory cells as potential sources of
Tx. For this purpose, rats were given a daily oral dose of CsA
(50 mg/kg, N = 6) or vehicle (N = 6) for 30 days. Following the
in vivo treatment, kidneys from CsA and vehicle treated
animals were isolated and perfused ex vivo in a recirculating
cell-free perfusion system at a constant pressure of 100 mm Hg.
This system permits the determination of renal TxA2 generation
without systemic contamination. Each kidney was allowed 20
minutes to equilibrate after beginning the perfusion. Then a 20
minute experimental clearance period was performed. Urine
samples were collected in preweighed tubes. Midpoint clear-
ance samples of venous effluent perfusate were also taken.
Urine and effluent perfusate samples were frozen and stored at
—20°C until analysis. Glomerular filtration rate, estimated as
creatinine clearance, and perfusate flow rate, determined volu-
metrically, were evaluated throughout the experiment. Urine
samples were later thawed, extracted and assayed for TxB2 and
2,3-dinor-TxB2 by HRGC-NICIMS as described below. Renal
specimens from perfused kidneys were obtained after comple-
tion of the perfusion and processed for electron microscopy
examination.
To establish whether CsA may directly stimulate Tx produc-
tion from platelets or kidney cells, additional in vitro experi-
ments were performed evaluating the synthesis of i-TxB2 in
platelet rich plasma (PRP), isolated glomeruli, mesangial cells in
culture and tubular preparations in the presence of different
concentrations of CsA.
Renal function studies
Rats were anesthetized by intraperitoneal injection of thio-
pental sodium (50 mg/kg body wt). Surgical preparation con-
sisted of tracheostomy, cannulation of femoral artery and vein,
and placement of a large-bore polyethylene tube into the
bladder through a small suprapubic incision. A heated table
maintained body temperature at 37°C. Arterial blood pressure
was continuously monitored throughout the experiment directly
from the femoral artery by a polyethylene tube (PE-50), con-
nected to a pressure transducer and a carrier amplifier (Bat-
taglia Rangoni, Bologna, Italy). GFR and RPF were measured
by the clearance of inulin (E. Merck, Darmstadt, FRG) and
PAH (Sigma Chemical Co., St. Louis, Missouri, USA), respec-
tively. In 100 ml distilled water, 5 g inulin, 200 mg PAH, and 900
mg NaCI were dissolved. This saline solution (2 ml) containing
5% inulin and 0.2% PAH was infused in the femoral vein as a
priming load, followed by constant infusion of the same solution
via a syringe pump at 2 ml/hr. A 40-minute equilibration period
was allowed after surgery and initiation of infusion in order to
attain constant plasma levels of inulin and PAH. Clearance
periods, 30 minutes each, were performed in triplicate. At the
midpoint of each period, 100 il blood samples were obtained
from the femoral artery and plasma was separated by centrifu-
gation. Urine samples were collected from the bladder in
preweighed vessels. Plasma and urine inulin and PAH were
determined by methods previously described [16, 17] modified
for microliter samples.
Isolated perfused kidney studies
Perfusion procedure and apparatus. The perfusion technique
used in these experiments was a modification of that described
by Roblero et al [18] and Vio et al [19]. Rats were anesthetized
by an i.p. injection of thiopental sodium (50 mg/kg body wt) and
placed on a heated surgical table. The right kidney and retro-
peritoneal structures were exposed through a midline abdomi-
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nal incision. After the abdominal cavity was exposed, the
following steps were performed: 1.) The adrenal artery, which
arises from the right renal artery, was identified and tied; 2.) the
vena cava tributaries below the right renal pedicle and above
the iliac bifurcation were tied. Additional loose ligatures were
placed around the vena cava just above the right renal pedicle
and below the right renal vein; 3.) after i.v. injection of 0.5 ml
of 10% mannitol and 120 IU heparin, the right ureter was
isolated from the surrounding connective tissue and cannulated
with PE-lO polyethylene tubing (Clay-Adams, Parsippany, New
Jersey, USA); 4.) the open tip of a venous cannula (PE-240
polyethylene catheter) with its distal end closed was introduced
into the vena cava below the right renal vein and secured in
place; 5.) the distal end of the superior mesenteric artery was
tied and loose ligatures were placed around the superior mes-
entenc artery and the right renal artery near the aorta. Care was
taken to avoid excessive manipulation of the renal pedicle; 6.)
the renal artery was cannulated with a short, blunted 19-gauge
needle via the superior mesenteric artery to avoid interruption
of flow to the kidney; 7.) the arterial cannula was then secured
in place by the previously placed ligatures, the distal end of the
venous cannula was opened, and the ligature around the vena
cava above the right renal pedicle was tied; 8.) the kidney was
washed with 50 ml of perfusion solution until the venous
effluent was free of blood, as determined by the absence of the
peroxidase-like activity of hemoglobin (Hemastix strip). Then
the venous effluent was recirculated.
Venous outflow was collected into a small glass beaker and
returned to a reservoir (closed system) through a two-headed
Minipulse peristaltic pump (Gilson 2, Villier Le Bel, France).
The perfusion apparatus consisted of a plastic reservoir bottle
from which the perfusion medium passed to hollow-fiber mem-
brane oxygenator (Bellco, Mirandola, Italy). The perfusate was
drawn through the blood compartment of the oxygenator, and a
gas mixture (95% 02—5% C02) continuously passed through the
gas compartment, oxygenating the perfusion solution and hold-
ing its pH at 7.35 to 7.40. From the oxygenator the medium
passed through Tygon tubing to the second head of the peri-
staltic pump, an in-line 8 tm filter (Sartorius, Gottingen, FRG),
and a glass bubble trap. Finally the perfusate was delivered
through latex tubing to the renal artery cannula.
The perfusion medium was maintained at 37°C by a constant
Haake Dl temperature circulator (Haake, Berlin, FRG). Perfu-
sion pressure was continuously measured with a Statham
transducer (Gould, Dusseldorf, FRG) connected by polyethyl-
ene tubing to the perfusion line proximally to the arterial
cannula and recorded on a Battaglia Rangoni KY 135 recorder
(Battaglia Rangoni, Casalecchio di Reno, Bologna, Italy). Per-
fusion pressure was corrected by the pressure generated by the
catheter alone at each flow rate, and variations in perfusion
pressure were compensated for by changing the rate of the
peristaltic pump. Because the system was maintained at con-
stant pressure (100 mm Hg), changes in perfusate flow reflected
changes in renal vascular resistance.
Composition of the perfusate. The perfusate consisted of
Krebs-Henseleit buffer (120 mrvi NaC1, 25 msi NaHCO3, 2.8 mM
KC1, 2.5 mM CaCl2, 1.2 mrvi KH2PO4, and 1.5 mM MgSO4)
containing 3.5 g/lOO ml Ficoll 70 (Pharmacia Fine Chemicals,
Uppsala, Sweden), 1.0 g/100 ml bovine serum albumin (Pentex
BSA Fraction V, Miles Laboratories, Elkhart, Indiana, USA),
200 mg/l00 ml dextrose, 36 mgIlOO ml urea, 50 mg/l00 ml
creatinine and the following L-amino acids in mM: methionine,
0.5; alanine, 2.0; glycine, 2.0; serine, 2.0; arginine, 1.0; isoleu-
cine, 1.0; aspartic acid, 3.0; cysteine, 0.5. This perfusate was
filtered through a O.45-m membrane filter (Sartorius, Gottin-
gen, FRG) before use and, when equilibrated with the gas
mixture at 37°C, its pH was approximately 7.4. The total
volume of the perfusate was 250 ml.
Urine extraction
Because urine contains a complex mixture of AA metabolites
in addition to factors that may possibly interfere with any
antigen-antibody reaction, urinary samples were extracted be-
fore RIA as previously described [11]. Briefly, after the addition
of 6,000 dpm [3H]-TxB2 (New England Nuclear, Boston, Mas-
sachusetts, USA, 113 Ci/mmol) for the estimation of the recov-
ery (60 to 75%) urine (3 ml) was acidified to pH 3.5 and passed
through a disposable (C 18) column, (Sep-pak, Millipore, Mil-
ford, Massachusetts, USA) previously activated with methanol
and water. The column was subsequently eluted with water,
n-hexane and ethylacetate. The latter fraction was dried on a
rotary evaporator at 37°C. Silicic acid was dissolved in benzene
:ethylacetate (60:40, solvent A) and added to a small glass
column, which was washed with benzene : ethylacetate : metha-
nol (60:40:20, solvent B) and solvent A. The extracted residue
was resuspended in 0.2 ml of benzene : ethylacetate : methanol
(60:40: 10 solvent C) and 0.8 ml of solvent A and applied to the
silicic acid column. Prostaglandin (PG) fractions were eluted
with solvent A (fraction 1: PGA and PGB) and solvent B
(fraction 2: PGE and PGF). Fraction 2 containing TxB2 was
dried at 37°C on a rotary evaporator, redissolved in phosphate
buffer and frozen at —20°C until assay.
Serum TxB2 concentration
Serum for studying platelet i-TxB2 production in response to
endogenous thrombin was obtained by leaving multiple 1-ml
aliquots of native blood, collected by puncture of the tail vein,
at 37°C for 30 minutes, according to the method previously
reported [201. The prepared sera were frozen and stored at
—20°C until assayed.
Radioimmunoassay
I-TxB2 was measured as previously described [11]. Briefly,
samples were appropriately diluted in 0.02 M phosphate buffer
solution (PBS, pH 7.4) as follows: serum, 1: 10,000 to 1: 15,000;
PRP, 1:750 to 1:7,500; glomeruli, 1:250 to 1:300; mesangial
cells in culture, 1:30; tubular preparations, 1: 150 to 1:300; and
extracted urinary samples 1:20 to 1:50. [3H]-TxB2 (6,000 dpm)
and specific rabbit antibody (final dilution 1:250,000) were
incubated for 16 to 24 hours at 4°C. After the addition of human
PG-free plasma to prevent the adsorption to charcoal of anti-
body-bound Tx, separation of free from bound TxB2 was
obtained by rapid addition of 10 mg uncoated charcoal (Norit
A). After centrifugation, supernatant solution containing anti-
body-bound TxB2 was decanted directly into 8 ml Instagel II
(Packard Instruments Co. Inc., Downers Grove, Illinois, USA).
Radioactivity of samples was counted in a liquid scintillation
counter (LS 1800 Model; Beckman Instruments, Irvine, Cali-
fornia, USA). Results were expressed as nglml for serum,
ngIO.5 x platelets for PRP, nglmg protein for glomerular and
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tubular preparations, pg/b4 cells for mesangial cells in culture,
and ng/day for urine. The smallest concentration that could be
measured with 95% confidence was 2 pg/mI.
The cross-reactivity at 50% displacement of other arachidon-
ate metabolites with Tx antiserum was as follows: 100.0%
TxB2; 10.5% 2,3-dinor-TxB2; 0.023% PGF2,; 0.02% PGD2;
0.007 PGE2; <0.006% 2,3-dinor-6-keto-PGF1, and 6-keto-
PGF1; 0.004% 13, 14-dihydro-6, 1 5-keto-PGF1a, 13, 14-dihydro-
l5-keto-PGE2, 11, l5-bisdihydro-TxB2, leukotriene B4, leuko-
triene C4, leukotriene D4 and AA.
Intra-assay and inter-assay variability, evaluated by assays of
several serum samples, isolated glomeruli, mesangial cells in
culture, tubules and urine specimens, averaged 4 and 3%,
respectively, over a range of TxB2 concentrations from ito 100
pg/mi. Validation of urinary RIA measurements was obtained
by several independent criteria: dilution and recovery studies,
comparison among multiple antisera and characterization of the
chromatographic pattern of distribution of the extracted Tx-like
immunoreactivity on thin layer chromatography.
Urine extraction for mass spectrometry determination
TxB2 and 2,3-dinor-TxB2 were extracted from urine using an
immuno-affinity column obtained by coupling a rabbit antibody
raised against TxB2 (35% cross-reactivity with 2,3-dinor-TxB2)
to CNBr-activated Sepharose 4 B (Pharmacia, Uppsala, Swe-
den) as previously described [13]. Urine extraction was per-
formed as reported [13]. Briefly, 1 ml urine was mixed with 10
ml phosphate buffer (0.05 M, pH 7.4) containing known amounts
of deuterated internal standard (2 ng TxB2-D8). Preliminary
experiments showed that extraction efficiency from buffer was
similar for TxB2, 2,3-dinor-TxB2 and TxB2-D8. The diluted
urine was filtered, applied to the column and percolated at
reduced flow rate (about 0.5 mI/mm). The column was then
washed with water (10 ml) and left to dry. Then 0.5 ml
acetone: water (95:5) was placed in the column, the upper end
closed with a stopper and the lower end with a luer stopcock.
The column was then mechanically rotated for 15 minutes to
allow full prolonged contact between Ab-Se and eluent. The
column was then opened and the eluate collected into a small
reaction glass tube. An additional 1 ml acetone: water was then
added to the column and collected into the glass tube. The
eluate was dried under an air stream at room temperature, and
the pentafluorobenzyl ester (PFB), methyloxime, trimethylsilyl
ether (TMS) of Tx metabolites and TxB2-D8 were immediately
derivatized. The reaction was carried out as follows: 30 j.d
pentafluorobenzyl bromide: acetonitrile (1:2, vollvol) and 10 .d
diisopropylethylamine were added to the residue, heated at
40°C for five minutes and dried under a stream of air. This
procedure was repeated and the sample was thoroughly dried;
50 sl MOX were added, the reaction mixture was heated at
60°C for one hour, and then taken to dryness. After addition of
50 d BSTFA, the mixture was heated at 60°C for 15 minutes
and the sample was then ready for HRGC-NICIMS.
Recovery from urine for TxB2 and 2,3-dinor-TxB2 was about
50%.
High-resolution gas chromatography-negative ion chemical
ionization, mass spectrometry
A fully computerized VG 70-250 mass spectrometer equipped
with a DANI (Monza, Italy) 3800 gas chromatograph was used
in the chemical ionization negative ion mode. HRGC operating
conditions were: 26 m CP-Sil 5 CB (Chrompack, Middelburg,
The Netherlands) fused silica capillary column (0.32 mm i.d.;
0.13 m film thickness), oven temperature programming 140 to
280°C (1 mm isothermal, then 13°C/mm), septumless Pro-
grammed Temperature Vaporizer (PTV, DANI) splitless injec-
tion mode, and helium as carrier gas. NICIMS operating
conditions were: selected ion monitoring on carboxylate anions
(M-181), mlz 614 for TxB2, m/z 586 for 2,3-dinor-TxB2, m/z 622
for TxB2-D8, measuring time, 50 msec, inter-channel time, 10
msec; ammonia as reagent gas for chemical ionization; electron
energy: 50 eV; ionizer temperature, 200°C.
Histological studies
Light microscopy. Fragments of kidneys were fixed for 12
hours in Dubosq-Brazil, dehydrated in alcohol and embedded in
paraffin. The sections (3 js) were stained with hematoxylin and
eosin, Masson's trichrome, periodic acid-Schiff's reagent (PAS-
stain) and Wilder's reticulin.
Electron microscopy. Small tissue specimens of kidney were
fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4)
for four hours at 4°C. After three washes in cacodylate buffer
the samples were postfixed for one hour in 1% osmium at 4°C,
dehydrated through ascending grades of alcohol and embedded
in Epon. Semithin (0.5 ) sections were stained with 1%
toluidine blue in 0.5% sodium carbonate. Ultrathin (70 to 80 nm)
sections were examined with uranyl acetate and lead citrate
staining in a Zeiss EM 109 (Carl Zeiss, Oberkochen, FRG).
Glomerular isolation and incubation
Glomeruli were isolated as previously described [21]. Briefly,
animals were anesthetized with ether, the aorta was clamped
above the renal arteries, the renal veins were cut, and the
kidneys were perfused with 60 to 80 ml of Krebs-Ringer
phosphate buffer (KRB) with the following composition: 120.29
mM NaC1, 4.82 mst KC1, 1.21 mM MgSO4 and 15.6 mrvi
phosphate buffer (pH 7.4). All subsequent preparative steps
were performed at 4°C. The renal capsules were removed, the
cortex was separated from the medulla and finely minced to a
paste-like consistency. The homogenate was firstly gently passed
through a l06-pm stainless steel sieve which excluded the
tubules, and then washed with KRB over a 75-pm sieve which
retained the glomeruli. The glomeruli were suspended in ice-
cold KRB and allowed to settle spontaneously. The supernatant
was discarded and the pellet resuspended in the same buffer
solution. This washing step was repeated two more times. The
purity of isolated glomeruli was determined microscopically by
counting the number of glomerular and non-glomerular particles
suspended in a given volume. The final pellet consisted of
decapsulated glomeruli with less than 5% tubular contamina-
tion. For direct RIA measurements, isolated glomeruli were
centrifuged at 150 x g for five minutes, resuspended in KRB
supplemented with 2.57 mrvi CaCl2. Isolated glomeruli from
CsA and vehicle-treated rats were resuspended in 1 ml of KRB
at 37°C in room atmosphere in a Dubnoff shaking water bath.
Incubation was stopped after 60 minutes by centrifugation at
3,000 x g for five minutes and the supernatant of each tube was
collected and frozen until RIA for TxB2.
For in vitro studies isolated glomeruli from eight normal rats
were incubated 60 minutes with CsA, 0.5 j.M and 5 LM (final
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concentration), or with KRB plus ethanol, the vehicle in which
CsA was dissolved. Additional experiments were performed in
the presence of AA (60 p.M final concentration). The incubation
was stopped as described above, the supernatant collected and
stored at —20°C until RIA for TxB2.
Protein concentration, which ranged from 0.80 to 1.03 mg/mI,
was determined according to the method of Lowry et al [221.
Mesangial cells in culture preparation and incubation
Mesangial cell cultures were obtained from glomeruli isolated
from the rat kidney as described above. Collagenase treated
glomeruli were plated into culture dishes in Dulbecco's mini-
mum essential medium (D-MEM, Gibco, Paisley, UK) supple-
mented with 20% fetal calf serum (FCS, Gibco), penicillin (100
U/mI; Squibb S.p.a., Roma, Italy), streptomycin (100 p.g/ml;
Squibb) and amphotericin (0.25 p.g/ml; Gibco). Cells in culture
showed the typical previously described [23] spindle or stellate
morphology and contracted in response to angiotensin II.
Immunofluorescent staining of the cells was negative with
antibodies to factor VIII (Istituto Behring S.p.a., Scoppito,
L'Aquila, Italy) and was positive with antibodies to myosin and
actin (Bio-Yeda, Kiryat WeizmannlRehouot, Israel). Cells with
the morphological characteristics of epithelial cells were ab-
sent. Cells were studied as adherent monolayers following a
single passage.
Incubations were carried out in 35-mm diameter plastic
multiwells (Falcon, Labware Division of Becton Dickinson,
Milan, Italy) at the density of I X l0 cells/cm2. Confluent
monolayers were washed two times with 3 ml of PBS and then
incubated in D-MEM with 1% Tx-free FCS for 15 hours at 37°C
in the presence or absence of CsA or ethanol, the vehicle in
which CsA was dissolved. CsA was added to the cells at the
concentrations of 5, 10 and 50 p.M. At the end of the incubation,
the supernatant of each well was immediately frozen after
collection and was stored at —20°C until the RIA was per-
formed. Tx-free FCS was obtained removing TxB2 by three
passages of FCS in an immuno-affinity column obtained by
coupling an antiserum against TxB2 with Sepharose 4B as
previously described [13]. Selected experiments were also
performed with longer incubation periods (that is, 24, 48, 72 hr)
at CsA concentration of 5, 10, 50/kM.
Isolated proximal tubules preparation and incubation
Proximal tubule suspensions were prepared from kidneys of
eight Sprague-Dawley rats weighing 300 to 350 g, according to
the method described by Vinay, Gougoux and Lemieux [24].
For each experiment four rats were anesthetized with thiopen-
tal sodium intraperitoneally (50 mg/kg body wt). The kidneys
were removed and placed in ice-cold gassed (95% 02—5% C02)
Krebs-Henseleit saline (KHS) supplemented with 4 ms'i L-
lactate, 5 mr't D-glucose, 1 mi.s butyrate and 25 m sodium
bicarbonate (pH 7.4). Kidneys were cut into two halves along
the longitudinal axis and the medulla was carefully dissected
out. The resultant kidney cortex was then sliced using a
microtome. The cortical slices were pooled and washed three
times with KEIS. After resuspension in 10 ml of KHS containing
0.15 g/100 ml of collagenase (Clostridium histolyticum, Boeh-
ringer, Mannheim, FRG) and 0.5 ml of 10% (wt/vol) bovine
albumin (fraction V; Miles Laboratories, Cavenago, Italy), the
flasks were gassed, and the tissues were incubated at 37°C for
45 minutes with mechanical agitation to dissociate the tissue
into tubular fragments. At the end of the digestion procedure,
30 ml of ice cold KHS was added, the suspension was gently
shaken to disperse the fragments of tissue and filtered through
a tea stainer to remove the collagen fibers. After washing three
times in ice cold KHS, the remaining tissue was resuspended in
freshly prepared 50% Percoll solution as described previously
[24] and centrifuged for 30 minutes at 4°C at 12,200 x g on a
B-20 Beckman centrifuge equipped with a fixed-angle rotor
head. A band of almost pure proximal tubules was collected
from the Percoll gradient. The quality of the preparations was
tested by microscopic examination and positive periodic acid-
Schiff (PAS) staining of brush border membranes. The protein
content of tubule suspension was measured by the method of
Lowry et al [22]. Bovine serum albumin was used as a standard.
Freshly prepared isolated tubules were resuspended in 2 ml of
ice cold KHS at 37°C in a Dubnoff shaking water bath under
95% 02—5% CO2. Proximal tubule suspensions were incubated
for 60 minutes with CsA, 0.5 p.M and 5 p.M final concentration,
or with KHS plus ethanol, the vehicle in which CsA was
dissolved. Further experiments were performed in the presence
of AA (60 p.M final concentration), as a positive control. The
incubation was stopped by centrifugation at 225 x g for one
minute. The supernatant of each tube was collected, frozen and
stored at —20°C until RIA for TxB2. The pellet was used to
determine protein content for each tube which ranged from 8 to
14.30 mg/tube.
Platelet rich plasma (PRP) experiments
Blood was drawn from eight rats by cardiac venipuncture in
3.8 g% trisodium citrate (1: 10). PRP was obtained by centrifu-
gation at 200 x g for 15 minutes at room temperature; after PRP
was removed the residue blood sample was centrifuged at 2,000
x g for 10 minutes to obtain platelet poor plasma (PPP). The
PRP platelet count was adjusted to 5 X 105/j.d with autologous
PPP. Five tenths ml aliquots of PRP were preincubated five
minutes at room temperature with CsA (0.5 and S p.M) or
ethanol (the vehicle in which CsA was dissolved) and then
placed in a Born aggregometer (Elvi 840, Logos, Milano, Italy)
at 37°C under continuous stirring in the presence of 0.5 mr's AA
or 4 p.M ADP. These concentrations of AA or ADP were not
able to induce a maximal platelet stimulation since no irrevers-
ible aggregation was observed in response to these concentra-
tions of both stimuli. Three minutes after the addition of the
stimuli, samples were collected and frozen in liquid nitrogen
and stored at —20°C until TxB2 RIA was performed. Before
RIA, samples were thawed and centrifuged at 12,200 x g for 10
minutes on a B-20 Beckman centrifuge equipped with a fixed
angle rotor head. Supernatants were collected and diluted in
0.05 M phosphate buffer (pH 7.4).
Statistical analysis
All results are expressed as mean SD. Data were analyzed
by one-way analysis of variance. Significant level of differences
between groups was established by using Duncan's multiple-
range test.
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Table 1. Effect of 30 day cyclosporin A or vehicle administration on
renal function
GFR RPF
ml/min/100 g
CsA 0.34 0.06a 2.15 0.24
Vehicle 0.97 0.12 2.58 0.31
Values are mean SD; N = 10. Abbreviations are: GFR, glomerular
filtration rate; RPF, renal plasma flow; CsA, cyclosporin A.
Basal values (N = 5): GFR, 0.95 0.15 ml/min/100 g; RPF, 2.62
0.38 mlIminIlOO g.
a P < 0,01 vs. vehicle
Table 2. Serum thromboxane B2 in cyclosporin A and vehicle treated
rats
15
c 120
a)
I':
3
I'_
TxB2 2,3-dinor-TxB2
Fig. 1. Urinary excretion of TxB2 and 2,3-dinor-TxB2 measured by
GC-NICIMS after 30 days of CsA (U) or vehicle (EIJ) treatment. Values
are mean SD; N = 10 * < 0.01 versus vehicle. Basal values: TxB2,
1.12 0.38 ng/day; 2,3-dinor-TxB2, 1.60 0.34 ng/day.
Serum i-TxB2 concentration nglml
CsA Vehicle
DayO 229.20±60.11 192.70± 29.14
Day 30 190.56 64.79 204.75 28.60
1,00 2,3-dinor-TxB2
80
60
40
Values are mean SD; N = 10. Abbreviations are: i-TxB2, immune-
reactive thromboxane B2; CsA, cyclosporin A. Norm: 17m/z:586.34
Results
In vivo studies
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Renal function studies in rats treated with CsA. Table 1
shows the renal function changes induced by treatment with
100
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CsA. After 30 days of CsA administration all rats developed a
severe renal insufficiency. GFR was significantly decreased in 20
animals receiving CsA when compared to those given the
vehicle alone (Table 1). Comparable values ofGFR were found
between vehicle-treated and untreated (basal) rats (vehicle: 0.97
0.12; basal: 0.95 0.15 ml/min/100 g). At variance, CsA
treatment did not result in any significant change of RPF,
despite a lower mean value of RPF was observed as compared
to that of animals receiving the vehicle alone (Table 1). These
results are consistent with our previous findings [11].
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Urinary excretion of i-TxB2 and serum i-TxB2 concentration
in rats treated with CsA. In agreement with our previous
.
findings, in the group of animals studied here CsA induced a
significant (P < 0.01) increase in the urinary excretion of i-TxB2
Fig. 2 HRGC-N!CIMS analysis of TxB2 and 2,3-dinor-TxB2 in rat urine
after administration of CsA. After immuno-affinity extraction, the
sample was derivatized as the pentafluorobenzyl ester rnethyloxime and
trimethylsilyl ether. Carboxylate anions (M-181) of TxB2, 2,3-dinor-
in respect to pre-treatment values (CsA: day 0, 15.28 2.22; TxB2 and their deuterium-labeled internal standard (TxB2-D8) were
day 30: 44.39 5.23 ng/day). At variance vehicle administration
did not alter urinary i-TxB2 excretion (vehicle: day 0, 15.98
measured by selected ion monitoring. Relative intensity (%) is dis-
played on the y axis and time (min:sec) on the x axis.
2.83; day 30, 17.52 7.47 nglday). No differences however
were detectable in the serum i-TxB2 concentrations between
rats given CsA or vehicle (Table 2). higher amounts of both TxB2 and 2,3-dinor-TxB2 than the
Urinary excretion of TxB2 and 2,3-dinor-TxB2 in rats treated animals given the vehicle alone (TxB2-CsA, 11.86 0.17;
with CsA. To clarify whether the increase in urinary excretion TxB2-vehicle, 1.35 0.64 ng/day, P < 0.01; 2,3-dinor-TxB2-
of i-TxB2 was due to activation of circulating cells or resulted CsA, 6.92 1.30; 2,3-dinor-TxB2-vehicle, 1.80 0.59 ng/day,
from an effect of CsA on renal cell arachidonate metabolism, we P < 0.01). Basal values of urinary excretion of TxB2 and
measured urinary excretion of TxB2 and its metabolite, 2,3- 2,3-dinor-TxB2 were 1.12 0.38 ng/day and 1.60 0.34 ng/day,
dinor-TxB2, by gas chromatography-negative ion chemical ion- respectively. Furthermore, since GFR values were lower in
ization mass spectrometry. At least in man the 2,3-dinor me- CsA-treated rats, the values for both TxB2 and 2,3-dinor-TxB2
tabolite is considered the major urinary metabolite of TxB2 and excretion when expressed for milliliter of GFR were signifi-
reflects the generation of TxB2 by circulating cells which is cantly greater in animals given CsA than in rats receiving the
subsequently metabolized to 2,3-dinor-TxB2 before excretion, vehicle alone (TxB2-CsA, 6.56 0.60; TxB2-vehicle, 0.27
As shown in Figure 1 CsA-treated rats excreted significantly 0.15 pg/mI GFR, P <0.01; 2,3-dinor-TxB2-CsA, 3.85 0.90;
c'J
I
2,3-dinor-TxB2-vehicle, 0.36 0.15 pg/mi GFR, P < 0.01). A
representative chromatogram of urinary TxB2, 2 ,3-dinor-TxB2
and their deuterium-labeled internal standard (TxB2-D8) of rat
urine after 30-day CsA treatment is reported in Figure 2.
Ex vivo studies
Urinary excretion of TxB2 and 2,3-dinor-TxB2 in isolated
perfused kidneys from rats treated wit/i CsA or vehicle. To
further shed light on the relative contribution of resident renal
and circulating inflammatory cells to the urinary excretion of
TxB2 in CsA-treated animals, we measured by HRGC-NICIMS
the urinary excretion of TxB2 using an isolated perfused rat
kidney model in animals chronically (30 days) treated with CsA.
The absolute excretion of TxB2 was not significantly different
between rats given CsA and those treated with the vehicle alone
(TxB2-CsA, 3.81 0.72; TxB2-vehicle, 3.01 0.58 pg/mm).
However, the values for TxB2 excretion when expressed per
milliliter of GFR were significantly higher in CsA-treated ani-
mals than in rats given the vehicle alone (TxB2-CsA, 8.19
2.93; TxB2-vehicle, 3.29 0.94 pg/mI GFR, P < 0.05). The
percentage increase of urinary TxB2 excretion per milliliter of
GFR of CsA over vehicle-treated rat was higher in vivo than in
IPK (in vivo, 2430%; IPK, 249%). Moreover, the ratio 2,3-
dinor-TxB2/TxB2 urinary excretion obtained in vivo in rats
chronically treated with CsA was significantly higher as com-
pared with the ratio found in urinary samples of IPK from
CsA-treated animals (Fig. 3, top; in vivo, 0.58 0.11; IPK, 0.10
0.02, P < 0.01).
Glomerular generation of i-TxB2 in rats treated with CsA. In
rats given CsA, the generation of i-TxB2 from isolated glomeruli
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A
1.0 "In vivo" Isolated Perfused Kidney
0.8 *
0.6 ___
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Fig. 3. A. Comparison between the ratio of 2,3-dinor-TxB2/TxB2 urinary excretion measured by GC-N!CIMS after 30 days of CsA administration
obtained in vivo (0, N = JO) and in isolated perfused kidney preparations ( N = 6). Values are mean SD. J3 < 0.01 versus isolated perfused
kidney. B. Representative electron micrograph of a glomerulus from a rat chronically treated with CsA. Glornerular capillary lumens contain
inflammatory cells, consisting of mononuclear cells and polymorphonuclear leukocytes (uranyl acetate and lead citrate x 1,100). C. Representative
electron micrograph of a glomerulus from isolated perfused kidney preparation of a rat chronically treated with CsA. Note the absence of
inflammatory cells within glomerular capillary lumens (uranyl acetate and lead citrate X 1,100).
Benigni et a!: CsA nephrotoxicity and TxA2 synthesis 171
Fig. 5. Electron inicrograph of a glomerular capillary lumen from a rat
treated with CsA. Irregular doubling of basement membrane with
intramembranous round particles and focal loss of endothelial fenestrae
are present (uranyl acetate and lead citrate X 7,000).
Fig. 4. Electron micrographs of a glomerular capillary lumen from a
CsA -treated rat. Note the presence of infiltrating mononuclear cells (A).
Polymorphonuclear leukocytes are also recognizable (B) (uranyl acetate
and lead citrate x 3,000).
has been reported to be increased [25]. These results have been
confirmed here. Thus 30 day treatment with CsA resulted in a
significant (P < 0.01) increase in glomerular i-TxB2 generation
as compared to animals receiving the vehicle alone and to
control animals (CsA, 3.12 0.51; vehicle, 1.51 0.30;
control, 1.62 0.10 ng/mg protein).
Histological studies. Light and electron microscopy abnor-
malities were present in rats given CsA. Light microscopy
abnormalities were prevalent in the proximal tubules and char-
acterized by cytoplasmic isometric vacuolization. No light
microscopy abnormalities were detected at glomerular and
vascular level except for an intracapillary hypercellularity,
mainly due to inflammatory cells of monocyte type. Ultrastruc-
tural abnormalities of the proximal tubules were represented by
dilatation of smooth and rough endoplasmic reticulum and
occasional giant mitochondria. Electron microscopy provided
evidence of glomerular intracapillary hypercellularity primarily
of monocyte/macrophage type (Fig. 4) with few platelets.
Ultrastructural examination of glomerular capillary wall showed
focal abnormalities of both endothelium and glomerular base-
ment membrane. Mild glomerular endothelial damage, charac-
terized by focal loss of fenestrae, and focal doubling of glomer-
ular basement membrane were documented (Fig. 5), suggesting
that CsA exerts a toxic effect on these glomerular structures.
These abnormalities in turn may be responsible for activation of
blood borne cells recruited at glomerular level. At variance with
the above findings, isolated kidney preparations from animals
chronically treated with CsA (Fig. 3, bottom) did not show
accumulation of inflammatory cells within glomerular capillar-
ies.
In vitro studies
Effect of CsA on platelet i-TxB2 generation. To evaluate the
effect of CsA on platelet Tx generation, AA or ADP-stimulated
PRP was incubated with different CsA concentrations. The
concentrations of AA or ADP were chosen on the basis of the
fact that they were not able to induce irreversible platelet
aggregation and thus maximal platelet stimulation which could
mask a possible CsA effect on i-Tx112 generation. Our results
showed that pre-incubation with CsA (0.5 and S /LM) and
subsequent PRP stimulation with AA did not modify platelet
i-TxB2 generation in comparison to values obtained with AA
alone. Thus CsA (0.5 sM) + AA (0.5 mM) was 238.42 110.13
ng/0.5 x l0 platelets; CsA (5 LM) + AA (0.5 mM) was 274.62
81.90 ng/0.5 x l0 platelets; and AA (0,5 mM) was 269.85
116.71 ng/0.5 x l0 platelets. Similar findings were obtained
when rat PRP was incubated with CsA (0.5 p.M or 5 jsM) and
then challenged with ADP (4 p.M). Thus CsA (0.5 p.M) + ADP (4
4aM) was 6.28 1.27 ng/0.5 x l0 platelets; CsA (5 p.M) + ADP
(4 p.M) was 5.35 0.17 ng/0.5 X 1O platelets; ADP (4 p.M) was
5.43 1.85 ng/0.5 x l0 platelets.
an 4 ' r-t snasw
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rats
i-TxB2 production ng/mg protein
Proximal
Glomeruli tubules
Krebs 2.85 0.08 0.21 0.07
Krebs + Eth 2.96 0.48 0.25 0.03
CsA 0.5 /LM 2.65 0.05 0.20 0.05
CsA5 /SM 2.89 0.30 0.19 0.03
AA 60 /.LM 3.95 0.07a 1.03 o.l7
Effect of CsA on isolated glomeruli. To investigate whether
the direct exposure of isolated glomeruli to GsA may be
responsible for the increased Tx production, the effect of CsA
(0.5 and 5 sM) on i-TxB2 generation in isolated glomeruli from
normal rats was studied. As shown in Table 3 the in vitro
addition of CsA to glomeruli isolated from normal rats did not
influence the generation of i-TxB2, in contrast to that observed
in glomeruli isolated from rats given CsA for 30 days. Exoge-
nous AA (60 tM) added to isolated glomeruli was able to induce
a significant (P < 0.01) increase in i-TxB2 generation with
respect to the values obtained incubating the isolated glomeruli
in Krebs alone (Table 3).
Effect of GsA on mesangial cells in culture. To explore the
possibility that CsA may directly affect Tx production by
mesangial cells, the effect of different concentrations of CsA (5,
10 and 50 M) on Tx synthesis by mesangial cells in culture was
investigated. Figure 6 documents the concentration-dependent
inhibition induced by CsA on mesangial cell i-TxB2 generation
after 15 hours of incubation. Ethanol, the vehicle in which CsA
was dissolved, did not modify the mesangial cell i-TxB2 pro-
duction with respect to the values obtained with medium alone
(58.13 10.10 vs. 60.67 7.37 pg/liter x l0 cells). In the
presence of 5, 10 and 50 /.LM CsA, mesangial cell i-TxB2
production was reduced by 14% (52.20 6.56 pg/liter x 1O
cells), 29% (43.15 5.29 pg/liter X I0 cells) and 46% (33.05
1.73 pg/liter X iO cells), respectively, in comparison with the
values obtained with the medium alone. These results are in
agreement with previously reported data [261, showing an
inhibitory effect of CsA on PGE2 production by mesangial cells.
Prolonging the incubation period to 24 hours, i-TxB2 production
by mesangial cells in culture was not significantly changed by
different CsA concentrations (5, 10 and 50 jiM) with respect to
the medium or ethanol alone (CsA 24 hr: S jiM, 30.10 6.00; 10
jiM, 28.25 7.50; 50 jiM, 48.78 14.21; medium, 36.82 6.15;
ethanol, 30.75 8.30 pg/b4 cells). Similar results were ob-
tained after 48 and 72 hours of incubation (CsA 48 hr: 5 jiM,
35.15 5.20; 10 jiM, 46.14 2.35; 50 jiM, 40.82 2.75;
medium, 36.15 6.75; ethanol, 46.75 9.13 pg/b4 cells. CsA
72 hr: 5 jiM, 45.13 7.25; 10 jiM, 60.11 15.11; 50 jiM, 65.35
12.72; medium, 56.13 12.15; ethanol, 50.25 9.23 pg/104
cells).
Effect of GsA on suspension of proximal tubules. To deter-
mine whether CsA may &rectly modify the capacity of proxi-
Fig. 6. Concentration-dependent effect of Cs4 on i-TxB2 production by
mesangial cells in culture after 15 hour incubation. Each point repre-
sents the mean SD of 4 experiments; < 0.01 as compared to
medium alone. Symbols are: (El) medium alone; () ethanol; (•) CsA
5 jat;()CsA 10 s; (k) CsA 50 jiM.
mal tubules from normal rats to generate i-TxB2, the effect of in
vitro addition of CsA (0.5 and 5 jiM) Ofl Tx synthesis was
studied in pure suspension of proximal tubules. As shown in
Table 3, CsA was unable to affect i-TxB2 generation of isolated
proximal tubules compared to ethanol alone. Exogenous AA
(60 jiM) added to proximal tubules induced a significant (P <
0.01) increase in i-TxB2 generation with respect to the values
obtained incubating the isolated tubules in Krebs alone (Table
3).
Discussion
Our present results confirm previous studies and show that 30
day administration of CsA in rats is associated with a selective
increase in urinary i-TxB2 excretion which parallels the decline
in GFR. That the exaggerated urinary excretion of i-TxB2 may
have a functional significance has been suggested by previous
experiments showing the negative correlation between inulin
clearance and urinary i-TxB2 excretion and the protective effect
of a selective TxA2 synthase inhibitor on GFR [11]. This
interpretation is reinforced by the recent study of Elzinga and
coworkers [27], who demonstrated that the use of fish oil rich in
eicosapentaenoic acid as vehicle for CsA resulted in improved
renal function and morphology in the rat, associated with
depressed cortical levels of TxB2. Whether TxA2 can directly
influence renal hemodynamics as to lower vascular resistance
and Kf [281 or whether this is due to other [29—31] neuro-
hormonal regulators of GFR under the influence of TxA2 is open
to speculation.
With the present investigation we explored the possible
sources of the increased urinary i-TxB2 in CsA treated animals.
First the possibility that extrarenal platelet activation takes
place in CsA treated animals, which might contribute to the
excessive urinary excretion of i-TxB2, was examined. Failure to
observe an increase in i-TxB2 generation in serum of rats
treated with CsA with respect to control animals indicated that
CsA was unlikely to interfere with platelet AA metabolism at
the level of systemic circulation. That CsA might not interfere
directly with platelet AA metabolism was further supported by
Table 3. In vitro effect of cyclosporin A on thromboxane B2
production by isolated glomeruli and proximal tubules from normal 100
U)
U)0
x
0.
75
50
25Values are mean SD; N = 8. Abbreviations are: i-TxB2, immune-
reactive thromboxane B2; Eth, ethanol; CsA, cyclosporin A; AA,
arachidonic acid.
a P < 0.01 vs. Krebs, Krebs + Eth, CsA (0.5 jiM), CsA (5 jiM). 0
Time, 15 hours
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the finding of normal i-TxB2 generation in vitro of rat PRP
exposed to CsA and then challenged with AA or ADP. None of
these approaches, however, conclusively ruled out the possi-
bility that an extrarenal activation of platelets or other cells that
possess a Tx synthase machinery was responsible for the
increased urinary excretion of i-TxB2 in animals given CsA. In
particular, the fact that a CsA metabolite formed in vivo
interfered with platelet AA metabolism cannot be excluded. As
far as a possible renal source of the increased urinary i-TxB2 in
CsA treated animals, we have been unable to document that
exposure of isolated glomeruli, mesangial cells in culture or
proximal tubules to CsA leads to an increase in i-TxB2 gener-
ation with respect to the baseline values. However these are
acute experiments and it is possible that renal cells or tissue
need a prolonged exposure to CsA to orient their AA metabo-
lism toward an excessive production of TxB2.
The recent advances in understanding TxA2 metabolism in
vivo and the availability of reliable analytical methods to
measure the various urinary metabolites provide some interest-
ing tools to further approach the problem of extrarenal versus
renal origin of urinary TxB1 in CsA animals. Particularly, it has
been suggested that urinary excretion of the thromboxane
metabolite 2,3-dinor-TxB2 can be taken as a reliable marker of
in vivo chronic platelet activation, whereas urinary excretion of
TxB2 is more likely to reflect the renal synthesis of the parent
compound [15]. The excretion of 2,3-dinor-TxB,, the major
urinary Tx metabolite in man, is increased in severe atheroscle-
rosis [32, 331 and in other syndromes of platelet activation [34,
35]. Furthermore the in vivo administration of ASA, at a dose
which fully inhibits the capacity of platelet to form TxA2,
selectively inhibits the urinary excretion of 2,3-dinor-TxB2
without influencing urinary excretion of TxB2 [36]. Measure-
ment of urinary metabolites as a marker of in vivo Tx synthesis
avoids the problems related to measurement of TxB2 in plasma.
Actually plasma levels of TxB2 are highly unreliable because of
artifacts due to cx vivo platelet activation, which invariably
occurs during blood sampling.
We have documented here that in rats given CsA, the urinary
excretion of 2,3-dinor-TxB2 and TxB2 both increased over the
basal values to a statistically significant extent. These data are
in agreement with the recent findings of Coffman et al, who
found that in a postischemic denervated rat model, a 12 to 14
day treatment with CsA resulted in a decrease in renal function
associated with an increase in urinary excretion of TxB2 and
2,3-dinor-TxB2 [37]. Within the limits of the above mentioned
assumptions, these results would indicate that both circulating
cells and renal cells participate to the increased urinary excre-
tion of thromboxane metabolites in CsA-treated animals. As-
suming that CsA does not activate cell AA metabolism in the
systemic circulation, a theoretical possibility to explain our
results is that platelets or other blood derived cells are activated
during their passage through the kidney. Our ultrastructural
findings of a marked infiltration of blood borne cells, mainly of
monocyte-macrophage type in the glomerular tuft of CsA
treated animals, support this possibility.
To further discriminate between the relative contribution of
resident versus circulating inflammatory cells to the increased
urinary excretion of Tx in CsA treated animals, we performed a
number of experiments using the isolated rat kidney model.
Isolated perfused kidneys were prepared from animals previ-
ously treated with CsA (30 days) or vehicle, and TxB2 urinary
excretion values compared with urinary excretion values mea-
sured in vivo after 30 days of CsA administration. The perfusion
procedure removed virtually all the circulating inflammatory
cells entrapped within glomerular capillaries, as documented by
ultrastructural examination of IPK specimens. The data con-
firmed that isolated kidneys from animals treated with CsA had
a significantly higher TxB2 urinary excretion than isolated
kidneys from animals given the vehicle alone. However the
percentage increase in TxB2 urinary excretion of CsA over
vehicle treated animals was significantly lower in IPK than in
vivo. This indicates that both renal and circulating inflamma-
tory cells are likely to contribute to the exaggerated urinary
excretion of TxB2 observed in animals chronically given CsA.
In IPK we have also documented a lower ratio 2,3-dinor-TxB2/
TxB2 urinary excretion with respect to the ratio found in vivo,
indicating that in the latter condition circulating cells entrapped
within the glomerular circulation were the most likely source of
urinary excretion of 2,3-dinor-TxB2.
Why circulating inflammatory cells and platelets accumulate
within glomerular capillaries in CsA treated animals is open to
speculation. Recent studies showing that CsA can induce
endothelial damage [38] and that CsA nephrotoxicity is associ-
ated with a chronic type of arteriolar damage [39] support the
possibility that endothelial damage is the signal for platelets and
macrophages to accumulate within glomerular capillaries. Con-
sistent with this hypothesis is the finding of a mild focal
endothelial damage characterized by focal loss of endothelial
fenestrae and focal doubling of the basement membrane, asso-
ciated with mononuclear cell infiltrates in animals treated with
CsA. It is likely that CsA induced endothelial damage at the
renal circulation is associated with release of factor(s) that
activate platelets and macrophages during their passage through
the renal circulation.
In the attempt to reconcile the results of our biochemical
findings with morphological evidence of intracapillary hypercel-
lularity in vivo but not in IPK preparations, we suggest that
both resident and inflammatory cells contribute to the exagger-
ated urinary excretion of i-TxB2 in CsA treated animals. The
TxA2 formed by renal cells is excreted as TxB2, whereas the
TxA2 released by macrophages and platelets within the renal
circulation may at least in part return to the systemic circula-
tion, be metabolized and excreted as 2,3-dinor-TxB2. Future
studies addressing the biosynthesis, metabolism and renal han-
dling of TxA2 in rats will enable us to prove or disprove the
theoretical possibility that in the rat the kidney can metabolize
TxB, to 2,3-dinor-TxB2. As far as the relevance of findings in
rodents to the human situation, this will be another important
area for future comparative investigation since the low degree
of RPF fall and the marked hypercellularity are both peculiar
features of rats, less frequently seen in humans.
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